Skip to main content
SpringerLink
Log in

Antithrombotic therapy for the treatment of atrial fibrillation in the elderly

  • Published:
Journal of Interventional Cardiac Electrophysiology Aims and scope Submit manuscript

Abstract

Atrial fibrillation significantly raises the risk for ischemic stroke, and the prevalence of atrial fibrillation is increasing due to the aging of the population. Reducing the risk of ischemic stroke is one of the cornerstones in the medical management of atrial fibrillation. Oral vitamin K antagonists such as warfarin are highly effective in preventing atrial fibrillation-related thromboembolism, but can be challenging to manage and are associated with increased bleeding risk. Aspirin therapy has modest efficacy in reducing stroke risk, but is much less effective than warfarin. To help guide the choice of optimal antithrombotic therapy, risk stratification for stroke in atrial fibrillation may be helpful, although most elderly patients derive a net benefit from warfarin. Older patients have higher bleeding rates on warfarin and are at higher risk for intracranial hemorrhage. Although the risk of intracranial hemorrhage is generally quite low, its occurrence is associated with significant mortality and disability, and more effective methods to risk stratify patients for intracranial hemorrhage are needed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Wolf, P. A., Abbott, R. D., & Kannel, W. B. (1991). Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke, 22(8), 983–988.

    PubMed  CAS  Google Scholar 

  2. Fang, M. C., Stafford, R. S., Ruskin, J. N., & Singer, D. E. (2004). National trends in antiarrhythmic and antithrombotic medication use in atrial fibrillation. Archives of Internal Medicine, 164, 55–60.

    Article  PubMed  Google Scholar 

  3. Atrial Fibrillation Investigators (1994). Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: Analysis of pooled data from five randomized controlled trials. Archives of Internal Medicine, 154(13), 1449–1457.

    Article  Google Scholar 

  4. Ansell, J., Hirsh, J., Poller, L., Bussey, H., Jacobson, A., & Hylek, E. (2004). The pharmacology and management of the vitamin K antagonists: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 126(3_suppl), 204S–233.

    Article  PubMed  CAS  Google Scholar 

  5. Rieder, M. J., Reiner, A. P., Gage, B. F., et al. (2005). Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. The New England Journal of Medicine, 352(22), 2285–2293.

    Article  PubMed  CAS  Google Scholar 

  6. Garcia, D., Regan, S., Crowther, M., Hughes, R. A., & Hylek, E. M. (2005). Warfarin maintenance dosing patterns in clinical practice: Implications for safer anticoagulation in the elderly population. Chest, 127(6), 2049–2056.

    Article  PubMed  CAS  Google Scholar 

  7. Hart, R., Pearce, L. A., & Aguilar, M. I. (2007). Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Annals of Internal Medicine, 146, 857–867.

    PubMed  Google Scholar 

  8. Stroke Prevention in Atrial Fibrillation Investigators (1996). Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet, 348(9028), 633–638.

    Article  Google Scholar 

  9. Hylek, E., Skates, S., Sheehan, M., & Singer, D. (1996). An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. The New England Journal of Medicine, 335(8), 540–546.

    Article  PubMed  CAS  Google Scholar 

  10. Fang, M. C., Chang, Y., Hylek, E. M., et al. (2004). Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Annals of Internal Medicine, 141(10), 745–752.

    PubMed  Google Scholar 

  11. Mant, J., Hobbs, R., Fletcher, K., et al. (2007). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): A randomised controlled trial. Lancet, 370(9586), 493–503.

    Article  PubMed  CAS  Google Scholar 

  12. Rash, A., Downes, T., Portner, R., Yeo, W. W., Morgan, N., & Channer, K. S. (2007). A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO). Age and Ageing, 36(2), 151–156.

    Article  PubMed  Google Scholar 

  13. Bauer, K. A. (2006). New anticoagulants. Hematology, 450–456.

  14. Olsson, S. (2003). Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): Randomised controlled trial. Lancet, 362(9397), 1691–1698.

    Article  PubMed  CAS  Google Scholar 

  15. Albers, G. W., Diener, H. C., Frison, L., et al. (2005). Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: A randomized trial. Journal of the American Medical Association, 293(6), 690–698.

    Article  PubMed  Google Scholar 

  16. Perez-Gomez, F., Alegria, E., Berjon, J., et al. (2004). Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: A randomized multicenter study. Journal of the American College of Cardiology, 44(8), 1557–1566.

    Article  PubMed  CAS  Google Scholar 

  17. Shireman, T. I., Howard, P. A., Kresowik, T. F., & Ellerbeck, E. F. (2004). Combined anticoagulant-antiplatelet use and major bleeding events in elderly atrial fibrillation patients. Stroke, 35(10), 2362–2367.

    Article  PubMed  CAS  Google Scholar 

  18. Douketis, J. D., Arneklev, K., Goldhaber, S. Z., Spandorfer, J., Halperin, F., & Horrow, J. (2006). Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: Assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding. Archives of Internal Medicine, 166(8), 853–859.

    Article  PubMed  CAS  Google Scholar 

  19. Flaker, G. C., Gruber, M., Connolly, S. J., et al. (2006). Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: An exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. American Heart Journal, 152(5), 967–973.

    Article  PubMed  CAS  Google Scholar 

  20. Morocutti, C., Amabile, G., Fattapposta, F., et al. (1997). Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. SIFA (Studio Italiano Fibrillazione Atriale) Investigators. Stroke, 28(5), 1015–1021.

    PubMed  CAS  Google Scholar 

  21. ACTIVE Writing Group of the ACTIVE InvestigatorsConnolly, S., Pogue, J., et al. (2006). Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet, 367(9526), 1903–1912.

    Article  PubMed  CAS  Google Scholar 

  22. European Atrial Fibrillation Trial Study Group (1995). Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. The New England Journal of Medicine, 333, 5–10.

    Article  Google Scholar 

  23. Wang, T. J., Massaro, J. M., Levy, D., et al. (2003). A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: The Framingham Heart Study. Journal of the American Medical Association, 290(8), 1049–1056.

    Article  PubMed  Google Scholar 

  24. Hart, R., Pearce, L., McBride, R., Rothbart, R., & Asinger, R. (1999). Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: Analysis of 2012 participants in the SPAF I–III clinical trials. Stroke, 30, 1223–1229.

    PubMed  CAS  Google Scholar 

  25. Fang, M. C., Singer, D. E., Chang, Y., et al. (2005). Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: The AnTicoagulation and Risk Factors In Atrial Fibrillation (ATRIA) Study. Circulation, 112, 1687–1691.

    Article  PubMed  Google Scholar 

  26. Gage, B. F., Waterman, A. D., Shannon, W., Boechler, M., Rich, M. W., & Radford, M. J. (2001). Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. Journal of the American Medical Association, 285(22), 2864–2870.

    Article  PubMed  CAS  Google Scholar 

  27. Fang, M. C., Go, A. S., Chang, Y., Borowsky, L., Pomernacki, N. K., & Singer, D. E. (2008). Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation. Journal of the American College of Cardiology, 51(8), 810–815.

    Article  PubMed  Google Scholar 

  28. Baruch, L., Gage, B. F., Horrow, J., et al. (2007). Can patients at elevated risk of stroke treated with anticoagulants be further risk stratified? Stroke, 38(9), 2459–2463.

    Article  PubMed  CAS  Google Scholar 

  29. Healey, J. S., Hart, R. G., Pogue, J., et al. (2008). Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: The Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE-W). Stroke, 39(5), 1482–1486.

    Article  PubMed  CAS  Google Scholar 

  30. Hohnloser, S. H., Pajitnev, D., Pogue, J., et al. (2007). Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: An ACTIVE W Substudy. Journal of the American College of Cardiology, 50(22), 2156–2161.

    Article  PubMed  CAS  Google Scholar 

  31. Gage, B. F., Birman-Deych, E., Radford, M. J., Nilasena, D. S., & Binder, E. F. (2006). Risk of osteoporotic fracture in elderly patients taking warfarin: Results from the National Registry of Atrial Fibrillation 2. Archives of Internal Medicine, 166(2), 241–246.

    Article  PubMed  CAS  Google Scholar 

  32. Fang, M. C., Go, A. S., Hylek, E. M., et al. (2006). Age and the risk of warfarin-associated hemorrhage: The AnTicoagulation and Risk Factors In Atrial Fibrillation (ATRIA) Study. Journal of the American Geriatrics Society, 54(8), 1231–1236.

    Article  PubMed  Google Scholar 

  33. Fang, M. C., Go, A. S., Chang, Y., et al. (2007). Death and disability from warfarin-associated intracranial and extracranial hemorrhages. The American Journal of Medicine, 120(8), 700–705.

    Article  PubMed  Google Scholar 

  34. Schauer, D. P., Moomaw, C. J., Wess, M., Webb, T., & Eckman, M. H. (2005). Psychosocial risk factors for adverse outcomes in patients with nonvalvular atrial fibrillation receiving warfarin. Journal of General Internal Medicine, 20(12), 1114–1119.

    Article  PubMed  Google Scholar 

  35. Gage, B. F., Yan, Y., Milligan, P. E., et al. (2006). Clinical classification schemes for predicting hemorrhage: Results from the National Registry of Atrial Fibrillation (NRAF). American Heart Journal, 151(3), 713–719.

    Article  PubMed  Google Scholar 

  36. Kagansky, N., Knobler, H., Rimon, E., Ozer, Z., & Levy, S. (2004). Safety of anticoagulation therapy in well-informed older patients. Archives of Internal Medicine, 164(18), 2044–2050.

    Article  PubMed  Google Scholar 

  37. Landefeld, C. S., & Goldman, L. (1989). Major bleeding in outpatients treated with warfarin: Incidence and prediction by factors known at the start of outpatient therapy. The American Journal of Medicine, 87(2), 144–152.

    Article  PubMed  CAS  Google Scholar 

  38. Kuijer, P., Hutten, B., Prins, M., & Buller, H. (1999). Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Archives of Internal Medicine, 159, 457–460.

    Article  PubMed  CAS  Google Scholar 

  39. Shireman, T. I., Mahnken, J. D., Howard, P. A., Kresowik, T. F., Hou, Q., & Ellerbeck, E. F. (2006). Development of a contemporary bleeding risk model for elderly warfarin recipients. Chest, 130(5), 1390–1396.

    Article  PubMed  Google Scholar 

  40. Beyth, R., Quinn, L., & Landefeld, C. (1998). Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. The American Journal of Medicine, 105, 91–99.

    Article  PubMed  CAS  Google Scholar 

  41. Wells, P. S., Forgie, M. A., Simms, M., et al. (2003). The outpatient bleeding risk index: Validation of a tool for predicting bleeding rates in patients treated for deep venous thrombosis and pulmonary embolism. Archives of Internal Medicine, 163(8), 917–920.

    Article  PubMed  Google Scholar 

  42. Rosand, J., Hylek, E. M., O’Donnell, H. C., & Greenberg, S. M. (2000). Warfarin-associated hemorrhage and cerebral amyloid angiopathy. Neurology, 55, 947–957.

    PubMed  CAS  Google Scholar 

  43. O’Donnell, H., Rosand, J., Knudsen, K., et al. (2000). Apolipoprotein E genotype and the risk of recurrent lobar intracerebral hemorrhage. The New England Journal of Medicine, 342, 240–245.

    Article  PubMed  Google Scholar 

  44. Gage, B. F., Birman-Deych, E., Kerzner, R., Radford, M., Nilasena, D. S., & Rich, M. W. (2005). Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall. The American Journal of Medicine, 118, 612–617.

    Article  PubMed  Google Scholar 

  45. Hylek, E. M., D’Antonio, J., Evans-Molina, C., Shea, C., Henault, L. E., & Regan, S. (2006). Translating the results of randomized trials into clinical practice: The challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation. Stroke, 37(4), 1075–1080.

    Article  PubMed  Google Scholar 

  46. Man-Son-Hing, M., Nichol, G., Lau, A., & Laupacis, A. (1999). Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Archives of Internal Medicine, 159, 677–685.

    Article  PubMed  CAS  Google Scholar 

  47. Hylek, E. M., Evans-Molina, C., Shea, C., Henault, L. E., & Regan, S. (2007). Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation, 115(21), 2689–2696.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hospital Medicine, University of California at San Francisco, 533 Parnassus Ave., P. O. Box 0131, San Francisco, CA, 94143, USA

    Margaret C. Fang

Authors
  1. Margaret C. Fang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Margaret C. Fang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fang, M.C. Antithrombotic therapy for the treatment of atrial fibrillation in the elderly. J Interv Card Electrophysiol 25, 19–23 (2009). https://doi.org/10.1007/s10840-008-9334-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10840-008-9334-y

Keywords

Search

Navigation